A multifactorial model of T cell expansion and durable clinical benefit in response to a PD-L1 inhibitor.

by Mark D M Leiserson, Vasilis Syrgkanis, Amy Gilson, Miroslav Dudik, Sharon Gillett, Jennifer Chayes, Christian Borgs, Dean F Bajorin, Jonathan E Rosenberg, Samuel Funt, Alexandra Snyder, Lester Mackey
Published 2018-01-01